The trials and tribulations of drug development for functional gastrointestinal disorders

Neurogastroenterology and Motility

Volumn 20, Issue SUPPL. 1, 2008, Pages 130-138

  Chang, L ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Drug development; Functional gastrointestinal disorders; Irritable bowel syndrome; Treatment

Indexed keywords

BIOLOGICAL MARKER;

CONSENSUS; DIGESTIVE SYSTEM FUNCTION DISORDER; DISEASE SEVERITY; DRUG DEVELOPMENT; ECONOMIC ASPECT; HEALTH CARE COST; HUMAN; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PATIENT EDUCATION; PATIENT SATISFACTION; PREVALENCE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; TREATMENT RESPONSE;

ANIMALS; CLINICAL TRIALS AS TOPIC; DRUG DESIGN; GASTROINTESTINAL AGENTS; GASTROINTESTINAL DISEASES; HUMANS; TECHNOLOGY, PHARMACEUTICAL;

EID: 41949087718     PISSN: 13501925     EISSN: 13652982     Source Type: Journal    
DOI: 10.1111/j.1365-2982.2008.01093.x     Document Type: Review

References (70)

1. Longstreth GF, Thompson WG, Chey WD et al. Functional bowel disorders. Gastroenterology 2006 130 : 1480 91.
2. Lembo A. Irritable bowel syndrome medications side effects survey. J Clin Gastroenterol 2004 38 : 776 81.
3. Sandler RS, Everhart JE, Donowitz M et al. The burden of selected digestive diseases in the United States. Gastroenterology 2002 122 : 1500 11.
4. Mundy C, Dreyfus B, DiModica L. Irritable Bowel Syndrome. 2007. Available at: http://www.decisionresources.com/stellent/groups/public/documents/abstract/ 07mo02-abstract.hcsp (last accessed on 14 January 2008).
5. Mitchell CM, Drossman DA. Survey of the AGA membership relating to patients with functional gastrointestinal disorders. Gastroenterology 1987 92 : 1282 4.
6. Drossman DA, Camilleri M, Mayer EA et al. AGA technical review on irritable bowel syndrome. Gastroenterology 2002 123 : 2108 31.
7. Drossman DA. The functional gastrointestinal disorders and the Rome III process. Gastroenterology 2006 130 : 1377 90.
8. Dennison C, Prasad M, Lloyd A et al. The health-related quality of life and economic burden of constipation. Pharmacoeconomics 2005 23 : 461 76.
9. Sonnenberg A, Koch TR. Epidemiology of constipation in the United States. Dis Colon Rectum 1989 32 : 1 8.
10. Saito YA, Schoenfeld P, Locke GR III. The epidemiology of irritable bowel syndrome in North America: a systematic review. Am J Gastroenterol 2002 97 : 1910 5.
11. El-Serag HB, Talley NJ. Systemic review: the prevalence and clinical course of functional dyspepsia. Aliment Pharmacol Ther 2004 19 : 643 54.
12. Drossman DA, Li Z, Andruzzi E et al. US householder survey of functional gastrointestinal disorders. Prevalence, sociodemography and health impact. Dig Dis Sci 1993 38 : 1569 80.
13. Levy RL, Whitehead WE, Von Korff MR et al. Intergenerational transmission of gastrointestinal illness behavior. Am J Gastroenterol 2000 95 : 451 6.
14. Hungin AP, Whorwell PJ, Tack J et al. The prevalence, patterns and impact of irritable bowel syndrome: an international survey of 40,000 subjects. Aliment Pharmacol Ther 2003 17 : 643 50.
15. Muller-Lissner SA, Bollani S, Brummer RJ et al. Epidemiological aspects of irritable bowel syndrome in Europe and North America. Digestion 2001 64 : 200 4.
16. Taub E, Cuevas JL, Cook EW et al. Irritable bowel syndrome defined by factor analysis. Gender and race comparisons. Dig Dis Sci 1995 40 : 2647 55.
17. Nyrop KA, Palsson OS, Levy RL et al. Costs of health care for irritable bowel syndrome, chronic constipation, functional diarrhoea and functional abdominal pain. Aliment Pharmacol Ther 2007 26 : 237 48.
18. Pare P, Gray J, Lam S et al. Health-related quality of life, work productivity, and health care resource utilization of subjects with irritable bowel syndrome: baseline results from LOGIC (Longitudinal Outcomes Study of Gastrointestinal Symptoms in Canada), a naturalistic study. Clin Ther 2006 28 : 1726 35 discussion 1710 1.
19. Reilly MC, Bracco A, Ricci JF et al. The validity and accuracy of the Work Productivity and Activity Impairment questionnaire - irritable bowel syndrome version (WPAI:IBS). Aliment Pharmacol Ther 2004 20 : 459 67.
20. Sonnenberg A, Everhart JE, Brown DM. The Economic Costs of Types of Functional Constipation. In : Kamm MA, Lennard-Jones JE, eds. Constipation. Bristol, PA : Wrightson Biomedical Pub Ltd, 1994 : 19 29.
21. Passmore AP. Economic aspects of pharmacotherapy for chronic constipation. Pharmacoeconomics 1995 7 : 14 24.
22. Olden K, DeGarmo RG, Jhingran P et al. Patient satisfaction with alosetron for the treatment of women with diarrhea-predominant irritable bowel syndrome. Am J Gastroenterol 2002 97 : 3139 46.
23. Lembo A, Ameen VZ, Drossman DA. Irritable bowel syndrome: toward an understanding of severity. Clin Gastroenterol Hepatol 2005 3 : 717 25.
24. Spiegel BM, Gralnek IM, Bolus R et al. Clinical determinants of health-related quality of life in patients with irritable bowel syndrome. Arch Intern Med 2004 164 : 1773 80.
25. Lee OY, FitzGerald LZ, Naliboff B et al. Impact of advertisement and clinic populations in symptoms and perception of irritable bowel syndrome. Aliment Pharmacol Ther 1999 13 : 1631 8.
26. Tillisch K, Labus JS, Naliboff BD et al. Characterization of the alternating bowel habit subtype in patients with irritable bowel syndrome. Am J Gastroenterol 2005 100 : 896 904.
27. Spiegel BM, Farid M, Esrailian E et al. Is irritable bowel syndrome (IBS) a diagnosis of exclusion? A survey of primary care providers, gastroenterologists, and IBS experts. Gastroenterology 2006 130 : A-111.
28. Lesbros-Pantoflickova D, Michetti P, Fried M et al. Meta-analysis: the treatment of irritable bowel syndrome. Aliment Pharmacol Ther 2004 20 : 1253 69.
29. Bijkerk CJ, Muris JW, Knottnerus JA et al. Systematic review: the role of different types of fibre in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther 2004 19 : 245 51.
30. Brandt LJ, Bjorkman D, Fennerty MB et al. Systematic review on the management of irritable bowel syndrome in North America. Am J Gastroenterol 2002 97 : S7 26.
31. Mayer EA, Naliboff BD, Craig AD. Neuroimaging of the brain-gut axis: from basic understanding to treatment of functional GI disorders. Gastroenterology 2006 131 : 1925 42.
32. Drossman DA, Toner BB, Whitehead WE et al. Cognitive-behavioral therapy versus education and desipramine versus placebo for moderate to severe functional bowel disorders. Gastroenterology 2003 125 : 19 31.
33. Tack J, Broekaert D, Fischler B et al. A controlled cross-over study of the selective serotonin reuptake inhibitor citalopram in irritable bowel syndrome. Gut 2006 55 : 1095 103.
34. Lackner JM, Jaccard J, Krasner SS et al. How does cognitive behavior therapy for IBS work?: A mediational analysis of a randomized clinical trial. Gastroenterology 2007 133 : 433 44.
35. Whorwell PJ. Review article: the history of hypnotherapy and its role in the irritable bowel syndrome. Aliment Pharmacol Ther 2005 22 : 1061 7.
36. Cremonini F, Delgado-Aros S, Camilleri M. Efficacy of alosetron in irritable bowel syndrome: a meta-analysis of randomized controlled trials. Neurogastroenterol Motil 2003 15 : 79 86.
37. Berman SM, Chang L, Suyenobu B et al. Condition-specific deactivation of brain regions by 5-HT3 receptor antagonist alosetron. Gastroenterology 2002 123 : 969 77.
38. Viramontes B, McKinzie S, Pardi DS et al. Alosetron retards small bowel and overall colonic transit in diarrhea-predominant irritable bowel syndrome (D-IBS). Gastroenterology 2000 118 : A848.
39. Delvaux M, Louvel D, Mamet JP et al. Effect of alosetron on responses to colonic distension in patients with irritable bowel syndrome. Aliment Pharmacol Ther 1998 12 : 849 55.
40. Whorwell PJ, McCallum M, Creed FH et al. Non-colonic features of irritable bowel syndrome. Gut 1986 27 : 37 40.
41. Whitehead WE, Palsson O, Jones KR. Systemic review of the comorbidity of irritable bowel syndrome with other disorders: what are the causes and implications? Gastroenterology 2002 122 : 1140 56.
42. Crofford LJ. Violence, stress, and somatic syndromes. Trauma Violence Abuse 2007 8 : 299 313.
43. Yunus MB. Fibromyalgia and overlapping disorders: the unifying concept of central sensitivity syndromes. Semin Arthritis Rheum 2007 36 : 339 56.
44. Mayer EA, Bradesi S, Chang L et al. Functional GI disorders: from animal models to drug development. Gut 2007 In press).
45. Camilleri M, Chey WY, Mayer EA et al. A randomized controlled clinical trial of the serotonin type 3 receptor antagonist alosetron in women with diarrhea-predominant irritable bowel syndrome. Arch Intern Med 2001 161 : 1733 40.
46. Camilleri M, Mayer EA, Drossman DA et al. Improvement in pain and bowel function in female irritable bowel patients with alosetron, a 5-HT3 receptor antagonist. Aliment Pharmacol Ther 1999 13 : 1149 59.
47. Camilleri M, Northcutt AR, Kong S et al. Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised placebo-controlled trial. Lancet 2000 355 : 1035 40.
48. Lembo AJ, Olden KW, Ameen VZ et al. Effect of alosetron on bowel urgency and global symptoms in women with severe, diarrhea-predominant irritable bowel syndrome: analysis of two controlled trials. Clin Gastroenterol Hepatol 2004 2 : 675 82.
49. Kellow J, Lee OY, Chang FY et al. An Asia-Pacific, double blind placebo controlled, randomised study to evaluate the efficacy, safety, and tolerability of tegaserod in patients with irritable bowel syndrome. Gut 2003 52 : 671 6.
50. Nyhlin H, Bang C, Elsborg L et al. A double-blind, placebo-controlled, randomized study to evaluate the efficacy, safety and tolerability of tegaserod in patients with irritable bowel syndrome. Scand J Gastroenterol 2004 39 : 119 26.
51. Patel SM, Stason WB, Legedza A et al. The placebo effect in irritable bowel syndrome trials: a meta-analysis. Neurogastroenterol Motil 2005 17 : 332 40.
52. Pitz M, Cheang M, Bernstein CN. Defining the predictors of the placebo response in irritable bowel syndrome. Clin Gastroenterol Hepatol 2005 3 : 237 47.
53. Drossman DA, Chey W, Panas R et al. Lubiprostone significantly improves symptom relief rates in adults with irritable bowel syndrome and constipation (IBS-C): data from two twelve week, randomized, placebo controlled double blind trials. Gastroenterology 2007 132 : 2586 7.
54. Whitehead WE, Crowell MD, Bosmajian L et al. Existence of irritable bowel syndrome supported by factor analysis of symptoms in two community samples. Gastroenterology 1990 98 : 336 40.
55. Talley NJ, Boyce P, Jones M. Identification of distinct upper and lower gastrointestinal symptom groupings in an urban population. Gut 1998 42 : 690 5.
56. Whitehead WE, Bassotti G, Palsson O et al. Factor analysis of bowel symptoms in US and Italian populations. Dig Liver Dis 2003 35 : 774 83.
57. Camilleri M, Dubois D, Coulie B et al. Prevalence and socioeconomic impact of upper gastrointestinal disorders in the United States: results of the US Upper Gastrointestinal Study. Clin Gastroenterol Hepatol 2005 3 : 543 52.
58. Westbrook JI, Talley NJ. Empiric clustering of dyspepsia into symptom subgroups: a population-based study. Scand J Gastroenterol 2002 37 : 917 23.
59. Spiegel BM, Strickland A, Chang L. Predictors of patient-assessed illness severity in irritable bowel syndrome (IBS). Gastroenterology 2007 132 : A-680.
60. Spiegel BMR, Gralnek IM, Mayer EA et al. Clinical determinants of health-related quality of life in irritable bowel syndrome. Gastroenterology 2003 124 : A398.
61. Irvine EJ, Whitehead WE, Chey WD et al. Design of treatment trials for functional gastrointestinal disorders. Gastroenterology 2006 130 : 1538 51.
62. Guyatt GH, Feeny DH, Patrick DL. Measuring health-related quality of life. Ann Intern Med 1993 118 : 622 9.
63. Kamm MA. Review article: the complexity of drug development for irritable bowel syndrome. Aliment Pharmacol Ther 2002 16 : 343 51.
64. Chang L, Chey WD, Harris L et al. Incidence of ischemic colitis and serious complications of constipation among patients using alosetron: systematic review of clinical trials and post-marketing surveillance data. Am J Gastroenterol 2006 101 : 1069 79.
65. Lembo T, Wright RA, Bagby B et al. Alosetron controls bowel urgency and provides global symptom improvement in women with diarrhea-predominant irritable bowel syndrome. Am J Gastroenterol 2001 96 : 2662 70.
66. Krause R, Ameen V, Gordon SH et al. A randomized, double-blind, placebo-controlled study to assess efficacy and safety of 0.5 mg and 1 mg alosetron in women with severe diarrhea-predominant IBS. Am J Gastroenterol 2007 102 : 1709 19.
67. Carter EGS, Heath AT, Broadwell NE. The safety profile of alosetron since reintroduction under the risk management program. Gastroenterology 2007 132 : A-141.
68. FDA. FDA Permits Restricted Use of Zelnorm for Qualifying Patients. 2007. Available at: http://www.fda.gov/bbs/topics/NEWS/2007/NEW01673.html (last accessed on 14 January 2008).
69. Martinez-Gonzalez J, Badimon L. Mechanisms underlying the cardiovascular effects of COX-inhibition: benefits and risks. Curr Pharm Des 2007 13 : 2215 27.
70. Baker DE. Natalizumab: overview of its pharmacology and safety. Rev Gastroenterol Disord 2007 7 : 38 46.